{"id":24114,"date":"2022-11-23T20:10:00","date_gmt":"2022-11-23T12:10:00","guid":{"rendered":"https:\/\/flcube.com\/?p=24114"},"modified":"2025-01-30T20:25:02","modified_gmt":"2025-01-30T12:25:02","slug":"sun-novo-pharma-to-acquire-mah-rights-for-azilsartan-from-baiao-pharma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=24114","title":{"rendered":"Sun-Novo Pharma to Acquire MAH Rights for Azilsartan from Baiao Pharma"},"content":{"rendered":"\n

China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621<\/a>) has announced plans to acquire the Marketing Authorization Holder (MAH) rights to Beijing Baiao Pharmaceuticals Co., Ltd\u2019s generic version of Takeda Pharmaceutical Co., Ltd’s azilsartan (20mg, 40mg) for RMB 36.05 million (USD 5.04 million). The deal is structured to transfer the MAH rights to a third party, aiming to avoid horizontal competition.<\/p>\n\n\n\n

Deal Structure and Background<\/strong>
According to the transfer agreement between Baiao Pharma and Shandong Haiya Pharmaceutical Technology Co., Ltd, the MAH rights were originally set to be transferred to Haiya Pharmaceutical upon the drug\u2019s marketing approval in August 2022. However, the parties recently agreed to transfer the rights to a third party. To comply with the commitment letter related to horizontal competition and conflict of interest signed by the actual controller, Baiao Pharma intends to transfer the rights and interests of azilsartan to a third party through the transaction with Sun-Novo Pharma. The quoted price of RMB 36.05 million (USD 5.04 million) reflects the cost of accumulated research and development investment, not the valuation of the product itself.<\/p>\n\n\n\n

Drug Profile<\/strong>
Azilsartan is a next-generation selective AT1 subtype angiotensin II receptor antagonist (ARB) that works by combining with the angiotensin II receptor to inhibit vasoconstriction, reduce peripheral vascular tension, and achieve a hypotensive effect. The originator drug was approved in Japan in January 2012 but has not yet been approved in China, where Hengrui Medicine\u2019s generic version was the first to hit the market.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced plans to acquire the…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3412,31,3413,1262,2604,345],"class_list":["post-24114","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-baiao-pharmaceuticals","tag-generic-drugs","tag-haiya-pharmaceutical-technology","tag-sha-688621","tag-sun-novo-pharmaceutical-research","tag-takeda"],"yoast_head":"\nSun-Novo Pharma to Acquire MAH Rights for Azilsartan from Baiao Pharma - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced plans to acquire the Marketing Authorization Holder (MAH) rights to Beijing Baiao Pharmaceuticals Co., Ltd\u2019s generic version of Takeda Pharmaceutical Co., Ltd's azilsartan (20mg, 40mg) for RMB 36.05 million (USD 5.04 million). The deal is structured to transfer the MAH rights to a third party, aiming to avoid horizontal competition.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=24114\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sun-Novo Pharma to Acquire MAH Rights for Azilsartan from Baiao Pharma\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=24114\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-23T12:10:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-30T12:25:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24114#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24114\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sun-Novo Pharma to Acquire MAH Rights for Azilsartan from Baiao Pharma\",\"datePublished\":\"2022-11-23T12:10:00+00:00\",\"dateModified\":\"2025-01-30T12:25:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24114\"},\"wordCount\":256,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Baiao Pharmaceuticals\",\"Generic drugs\",\"Haiya Pharmaceutical Technology\",\"SHA: 688621\",\"Sun-Novo Pharmaceutical Research\",\"Takeda\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24114#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24114\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=24114\",\"name\":\"Sun-Novo Pharma to Acquire MAH Rights for Azilsartan from Baiao Pharma - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-11-23T12:10:00+00:00\",\"dateModified\":\"2025-01-30T12:25:02+00:00\",\"description\":\"China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced plans to acquire the Marketing Authorization Holder (MAH) rights to Beijing Baiao Pharmaceuticals Co., Ltd\u2019s generic version of Takeda Pharmaceutical Co., Ltd's azilsartan (20mg, 40mg) for RMB 36.05 million (USD 5.04 million). The deal is structured to transfer the MAH rights to a third party, aiming to avoid horizontal competition.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24114#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24114\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24114#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sun-Novo Pharma to Acquire MAH Rights for Azilsartan from Baiao Pharma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sun-Novo Pharma to Acquire MAH Rights for Azilsartan from Baiao Pharma - Insight, China's Pharmaceutical Industry","description":"China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced plans to acquire the Marketing Authorization Holder (MAH) rights to Beijing Baiao Pharmaceuticals Co., Ltd\u2019s generic version of Takeda Pharmaceutical Co., Ltd's azilsartan (20mg, 40mg) for RMB 36.05 million (USD 5.04 million). The deal is structured to transfer the MAH rights to a third party, aiming to avoid horizontal competition.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=24114","og_locale":"en_US","og_type":"article","og_title":"Sun-Novo Pharma to Acquire MAH Rights for Azilsartan from Baiao Pharma","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=24114","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-11-23T12:10:00+00:00","article_modified_time":"2025-01-30T12:25:02+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=24114#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=24114"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sun-Novo Pharma to Acquire MAH Rights for Azilsartan from Baiao Pharma","datePublished":"2022-11-23T12:10:00+00:00","dateModified":"2025-01-30T12:25:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=24114"},"wordCount":256,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Baiao Pharmaceuticals","Generic drugs","Haiya Pharmaceutical Technology","SHA: 688621","Sun-Novo Pharmaceutical Research","Takeda"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=24114#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=24114","url":"https:\/\/flcube.com\/?p=24114","name":"Sun-Novo Pharma to Acquire MAH Rights for Azilsartan from Baiao Pharma - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-11-23T12:10:00+00:00","dateModified":"2025-01-30T12:25:02+00:00","description":"China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced plans to acquire the Marketing Authorization Holder (MAH) rights to Beijing Baiao Pharmaceuticals Co., Ltd\u2019s generic version of Takeda Pharmaceutical Co., Ltd's azilsartan (20mg, 40mg) for RMB 36.05 million (USD 5.04 million). The deal is structured to transfer the MAH rights to a third party, aiming to avoid horizontal competition.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=24114#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=24114"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=24114#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sun-Novo Pharma to Acquire MAH Rights for Azilsartan from Baiao Pharma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24114","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24114"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24114\/revisions"}],"predecessor-version":[{"id":24117,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24114\/revisions\/24117"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24114"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24114"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24114"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}